You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 15, 2024

~ Buy the MULTAQ (dronedarone hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

MULTAQ Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Multaq, and what generic alternatives are available?

Multaq is a drug marketed by Sanofi Aventis Us and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-seven patent family members in twenty-eight countries.

The generic ingredient in MULTAQ is dronedarone hydrochloride. There are nineteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dronedarone hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Multaq

A generic version of MULTAQ was approved as dronedarone hydrochloride by LUPIN on January 31st, 2024.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for MULTAQ?
  • What are the global sales for MULTAQ?
  • What is Average Wholesale Price for MULTAQ?
Drug patent expirations by year for MULTAQ
Drug Prices for MULTAQ

See drug prices for MULTAQ

Drug Sales Revenue Trends for MULTAQ

See drug sales revenues for MULTAQ

Recent Clinical Trials for MULTAQ

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Duke Clinical Research InstitutePhase 4
American Heart AssociationPhase 4
University of UtahPhase 3

See all MULTAQ clinical trials

Paragraph IV (Patent) Challenges for MULTAQ
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
MULTAQ Tablets dronedarone hydrochloride 400 mg 022425 7 2013-07-01

US Patents and Regulatory Information for MULTAQ

MULTAQ is protected by five US patents.

Patents protecting MULTAQ

Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS

Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS

Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RHYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF

Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS

Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us MULTAQ dronedarone hydrochloride TABLET;ORAL 022425-001 Jul 1, 2009 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us MULTAQ dronedarone hydrochloride TABLET;ORAL 022425-001 Jul 1, 2009 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us MULTAQ dronedarone hydrochloride TABLET;ORAL 022425-001 Jul 1, 2009 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MULTAQ

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us MULTAQ dronedarone hydrochloride TABLET;ORAL 022425-001 Jul 1, 2009 ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us MULTAQ dronedarone hydrochloride TABLET;ORAL 022425-001 Jul 1, 2009 ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us MULTAQ dronedarone hydrochloride TABLET;ORAL 022425-001 Jul 1, 2009 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for MULTAQ

When does loss-of-exclusivity occur for MULTAQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 2950
Patent: USO DE DRONEDARONA PARA LA PREPARACION DE UN MEDICAMENTO PARA USO EN LA PREVENCION DE LA HOSPITALIZACION CARDIOVASCULAR O DE LA MORTALIDAD, COMPOSICION FARMACEUTICA, ARTICULO DE FABRICACION Y ENVASE
Estimated Expiration: ⤷  Sign Up

Patent: 2951
Patent: USO DE DRONEDARONA O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE ESTA, PARA LA PREPARACION DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE
Estimated Expiration: ⤷  Sign Up

Australia

Patent: 09252897
Patent: Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
Estimated Expiration: ⤷  Sign Up

Patent: 09252898
Patent: Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 0910631
Patent: uso de dronedarona para a preparação de um medicamento para uso na prevenção de hospitalização cardiovascular ou de mortalidade
Estimated Expiration: ⤷  Sign Up

Patent: 0911198
Patent: uso de dronedarona ou um sal farmaceutimente aceitável da mesma para a preparação de um medicamento para reguular o nível de potássio no sangue
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 21489
Patent: UTILISATION DE DRONEDARONE DANS UN MEDICAMENT UTILISE POUR PREVENIR UN EPISODE CARDIOVASCULAIRE MENANT A L'HOSPITALISATION OU A LA MORT (USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY)
Estimated Expiration: ⤷  Sign Up

Patent: 21491
Patent: UTILISATION DE LA DRONEDARONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI, POUR LA PREPARATION D'UN MEDICAMENT PERMETTANT LA REGULATION DU NIVEAU DE POTASSIUM DANS LE SANG (USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR THE PREPARATION OF A MEDICAMENT FOR REGULATING THE POTASSIUM LEVEL IN THE BLOOD)
Estimated Expiration: ⤷  Sign Up

Chile

Patent: 09000919
Patent: Uso de dronedarona o una sal farmaceuticamente aceptable para preparar un medicamento util en la prevencion y/o tratamiento de la hipocalemia.
Estimated Expiration: ⤷  Sign Up

Patent: 09000920
Patent: Uso de dronedarona o una sal farmaceuticamente aceptable para preparar un medicamento util para la prevencion de hospitalizaciones cardiovasculares.
Estimated Expiration: ⤷  Sign Up

China

Patent: 2065855
Patent: Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
Estimated Expiration: ⤷  Sign Up

Patent: 2065857
Patent: Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in regulating the potassium level in the blood
Estimated Expiration: ⤷  Sign Up

Colombia

Patent: 60064
Patent: USO DE DRONEDARONA PARA LA PREPARACION DE UN MEDICAMENTO PARA USO EN LA PREVENCION DE LA HOSPITALIZACION CARDIOVASCULAR O DE LA MORTALIDAD
Estimated Expiration: ⤷  Sign Up

Patent: 60065
Patent: USO DE DRONEDARONA O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE ESTA PARA LA PREPARACION DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE
Estimated Expiration: ⤷  Sign Up

Costa Rica

Patent: 721
Patent: USO DE DRONEDARONA PARA LA PREPARACIÓN DE UN MEDICAMENTO PARA USO EN LA PREVENCIÓN DE LA HOSPITALIZACIÓN CARDIOVASCULAR O DE LA MORTALIDAD
Estimated Expiration: ⤷  Sign Up

Patent: 734
Patent: USO DE DRONEDARONA O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE ESTA, PARA LA PREPARACION DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE
Estimated Expiration: ⤷  Sign Up

Dominican Republic

Patent: 010000299
Patent: USO DE DRONEDARONA PARA LA PREPARACION DE UN MEDICAMENTO PARA USO EN LA PREVENCION DE LA HOSPITALIZACION CARDIOVASCULAR O DE LA MORTALIDAD
Estimated Expiration: ⤷  Sign Up

Patent: 010000300
Patent: USO DE DRONEDARONA O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE ESTA, PARA LA PREPARACION DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE
Estimated Expiration: ⤷  Sign Up

Ecuador

Patent: 10010540
Patent: USO DE DRONEDARONA PARA LA PREPARACION DE UN MEDICAMENTO PARA USO EN LA PREVENCION DE LA HOSPITALIZACION CARDIOVASCULAR O DE LA MORTALIDAD
Estimated Expiration: ⤷  Sign Up

Patent: 10010553
Patent: USO DE DRONEDARONA O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE ESTA, PARA LA PREPARACION DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE
Estimated Expiration: ⤷  Sign Up

El Salvador

Patent: 10003700
Patent: USO DE DRONEDARONA PARA LA PREPARACION DE UN MEDICAMENTO PARA USO EN LA PREVENCION DE LA HOSPITALIZACION CARDIOVASCULAR O DE LA MORTALIDAD
Estimated Expiration: ⤷  Sign Up

Patent: 10003701
Patent: USO DE DRONEDARONA O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE ESTA, PARA LA PREPARACION DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 5017
Patent: СПОСОБ ЛЕЧЕНИЯ ПАЦИЕНТОВ С ИСТОРИЕЙ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ ИЛИ ТРЕПЕТАНИЯ ПРЕДСЕРДИЙ, ИЛИ СУЩЕСТВУЮЩИМИ ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ ИЛИ ТРЕПЕТАНИЕМ ПРЕДСЕРДИЙ, ПРЕДОТВРАЩАЮЩИЙ ГОСПИТАЛИЗАЦИЮ В КАРДИОЛОГИЧЕСКОЕ ОТДЕЛЕНИЕ (METHOD OF TREATING PATIENTS WITH A HISTORY OF ATRIAL FIBRILLATION OR ATRIAL FLUTTER, OR CURRENT ATRIAL FIBRILLATION OR ATRIAL FLUTTER, PREVENTING CARDIOVASCULAR HOSPITALIZATION)
Estimated Expiration: ⤷  Sign Up

Patent: 1071204
Patent: ПРИМЕНЕНИЕ ДРОНЕДАРОНА ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА ДЛЯ ПРИМЕНЕНИЯ В ПРЕДОТВРАЩЕНИИ ГОСПИТАЛИЗАЦИИ В КАРДИОЛОГИЧЕСКОЕ ОТДЕЛЕНИЕ ИЛИ СМЕРТНОСТИ
Estimated Expiration: ⤷  Sign Up

Patent: 1071209
Patent: ПРИМЕНЕНИЕ ДРОНЕДАРОНА ИЛИ ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМОЙ СОЛИ ДЛЯ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА ДЛЯ РЕГУЛЯЦИИ УРОВНЯ КАЛИЯ В КРОВИ
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 80701
Patent: UTILISATION DE DRONÉDARONE DANS UN MÉDICAMENT UTILISÉ POUR PRÉVENIR UN ÉPISODE CARDIOVASCULAIRE MENANT À L HOSPITALISATION OU À LA MORT (USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY)
Estimated Expiration: ⤷  Sign Up

Patent: 80702
Patent: UTILISATION DE LA DRONÉDARONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI, POUR LA PRÉPARATION D UN MÉDICAMENT PERMETTANT LA RÉGULATION DU NIVEAU DE POTASSIUM DANS LE SANG (USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR THE PREPARATION OF A MEDICAMENT FOR REGULATING THE POTASSIUM LEVEL IN THE BLOOD)
Estimated Expiration: ⤷  Sign Up

Patent: 84564
Patent: Utilisation de dronédarone dans un médicament utilisé pour prévenir un épisode cardiovasculaire menant à l’hospitalisation ou prévenir la fibrillation auriculaire (Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or in the prevention of atrial fibrillation)
Estimated Expiration: ⤷  Sign Up

Patent: 95862
Patent: UTILISATION DE LA DRONEDARONE DANS LA PREPARATION D'UN MEDICAMENT UTILISE POUR PREVENIR UN EPISODE CARDIOVASCULAIRE MENANT A L'HOSPITALISATION OU PREVENIR LA FIBRILLATION AURICULAIRE (USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR IN THE PREVENTION OF ATRIAL FIBRILLATION)
Estimated Expiration: ⤷  Sign Up

France

Patent: 30148
Patent: UTILISATION DE LA DRONEDARONE POUR LA PREPARATION D'UN MEDICAMENT DESTINE A LA PREVENTION DE L'HOSPITALISATION CARDIOVASCULAIRE OU DE LA MORTALITE (Use of dronedarone to prepare medicament to prevent mortality and/or cardiovascular hospitalizations in patients having e.g. history of atrial fibrillation/atrial flutter, cerebrovascular accident and non-rheumatic valvular heart disease)
Estimated Expiration: ⤷  Sign Up

Patent: 30150
Patent: UTILISATION DE LA DRONEDARONE POUR LA PREPARATION D'UN MEDICAMENT DESTINE A REGULER LE TAUX DE POTASSIUM DANS LE SANG
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 11518147
Estimated Expiration: ⤷  Sign Up

Patent: 11518785
Estimated Expiration: ⤷  Sign Up

Malaysia

Patent: 3608
Patent: USE OF DRONEDARONE FOR THE PREPARATION OF MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 10011400
Patent: USO DE DRONEDARONA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LO MISMO, PARA LA PREPARACION DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE. (USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR THE PREPARATION OF A MEDICAMENT FOR REGULATING THE POTASSIUM LEVEL IN THE BLOOD.)
Estimated Expiration: ⤷  Sign Up

Patent: 10011414
Patent: USO DE DRONEDARONA PARA LA PREPARACION DE UN MEDICAMENTO PARA USO EN LA PREVENCION DE LA HOSPITALIZACION CARDIOVASCULAR O DE LA MORTALIDAD. (USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY.)
Estimated Expiration: ⤷  Sign Up

Morocco

Patent: 354
Patent: استخدام الدرونيدارون في دواء يستخدم لمنع اضطرابات القلب والأوعية الدموية التي قد تؤدي إلى دخول المستشفى أو الوفاة
Estimated Expiration: ⤷  Sign Up

Patent: 356
Patent: استخدام الدرونيدارون أو ملح مقبول صيدليا ، لإعداد دواء لتنظيم مستوى البوتاسيوم في الدم
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 8623
Patent: Use of a medicament containing dronedarone with food for preventing cardiovascular hospitalization
Estimated Expiration: ⤷  Sign Up

Nicaragua

Patent: 1000172
Patent: USO DE DRONEDARONA PARA LA PREPARACIÓN DE UN MEDICAMENTO PARA USO EN LA PREVENCIÓN DE LA HOSPITALIZACIÓN CARDIOVASCULAR O DE LA MORTALIDAD.
Estimated Expiration: ⤷  Sign Up

Patent: 1000173
Patent: USO DE DRONEDARONA O UNA SAL ACEPTABLE FARMACÉUTICAMENTE DE ÉSTA, PARA LA PREPARACIÓN DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE.
Estimated Expiration: ⤷  Sign Up

Peru

Patent: 091777
Patent: DRONEDARONA O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE LA MISMA
Estimated Expiration: ⤷  Sign Up

Patent: 091809
Patent: USO DE DRONEDARONA PARA LA PREPARACION DE UN MEDICAMENTO PARA USO EN LA PREVENCION DE LA HOSPITALIZACION CARDIOVASCULAR O DE LA MORTALIDAD
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 1007248
Patent: USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY
Estimated Expiration: ⤷  Sign Up

Patent: 1007391
Patent: USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR THE PREPARATION OF A MEDICAMENT FOR REGULATING THE POTASSIUM IN THE BLOOD
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 100135814
Patent: USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR THE PREPARATION OF A MEDICAMENT FOR REGULATING THE POTASSIUM LEVEL IN THE BLOOD
Estimated Expiration: ⤷  Sign Up

Patent: 100135909
Patent: USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY
Estimated Expiration: ⤷  Sign Up

Taiwan

Patent: 19298
Estimated Expiration: ⤷  Sign Up

Patent: 0946108
Patent: Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
Estimated Expiration: ⤷  Sign Up

Patent: 0948354
Patent: Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
Estimated Expiration: ⤷  Sign Up

Patent: 1529068
Patent: Use of DRONEDARONE for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
Estimated Expiration: ⤷  Sign Up

Tunisia

Patent: 10000454
Patent: USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALISATION OR OF MORTATILY
Estimated Expiration: ⤷  Sign Up

Ukraine

Patent: 8980
Patent: ЗАСТОСУВАННЯ ДРОНЕДАРОНУ ДЛЯ ПРОФІЛАКТИКИ СЕРЦЕВО-СУДИННИХ ГОСПІТАЛІЗАЦІЙ (USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY)
Estimated Expiration: ⤷  Sign Up

Uruguay

Patent: 767
Patent: USO DE DRONEDARONA PARA LA PREPARACIÓN DE UN MEDICAMENTO PARA USO EN LA PREVENCIÓN DE LA HOSPITALIZACIÓN CARDIOVASCULAR O DE LA MORTALIDAD
Estimated Expiration: ⤷  Sign Up

Patent: 768
Patent: USO DE DRONEDARONA O UNA SAL ACEPTABLE FARMACÉUTICAMENTE DE ÉSTA, PARA LA PREPARACIÓN DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MULTAQ around the world.

Country Patent Number Title Estimated Expiration
Mexico 2010011400 USO DE DRONEDARONA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LO MISMO, PARA LA PREPARACION DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE. (USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR THE PREPARATION OF A MEDICAMENT FOR REGULATING THE POTASSIUM LEVEL IN THE BLOOD.) ⤷  Sign Up
Canada 2047773 DERIVES DE BENZOFURANE, DE BENZOTHIOPHENE, D'INDOLE ET D'INDOLIZINE, PROCEDES D'OBTENTION ET COMPOSITIONS QUI EN CONTIENNENT (DERIVATIVES OF BENZOFURAN, BENZOTHIOPHENE, INDOLE AND INDOLIZINE, PROCESS FOR THEIR PREPARATION AS WELL AS THE COMPOSITIONS CONTAINING THEM) ⤷  Sign Up
Hungary T62280 ⤷  Sign Up
Denmark 1007030 ⤷  Sign Up
Germany 69823360 ⤷  Sign Up
Poland 168044 ⤷  Sign Up
Denmark 0471609 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for MULTAQ

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1007030 PA2010003,C1007030 Lithuania ⤷  Sign Up PRODUCT NAME: DRONEDARONUM; REGISTRATION NO/DATE: EU/1/09/591/001, 2009 11 26 EU/1/09/591/002, 2009 11 26 EU/1/09/591/003, 2009 11 26 EU/1/09/591/004 20091126
1007030 384 Finland ⤷  Sign Up
1007030 10C0031 France ⤷  Sign Up PRODUCT NAME: DRONEDARONE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/591/001 DU 20091126; REGISTRATION NO/DATE AT EEC: EU/1/09/591/001-004 DU 20091126
1007030 SPC/GB10/029 United Kingdom ⤷  Sign Up PRODUCT NAME: DRONEDARONE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/09/591/001 20091126; UK EU/1/09/591/002 20091126; UK EU/1/09/591/003 20091126; UK EU/1/09/591/004 20091126
1007030 SPC008/2010 Ireland ⤷  Sign Up SPC008/2010: 20101015, EXPIRES: 20230616
1007030 PA2010003 Lithuania ⤷  Sign Up PRODUCT NAME: DRONEDARONUM; REGISTRATION NO/DATE: EU/1/09/591/001, 2009 11 26 EU/1/09/591/002, 2009 11 26 EU/1/09/591/003, 2009 11 26 EU/1/09/591/004 20091126
1007030 91673 Luxembourg ⤷  Sign Up 91673, EXPIRES: 20230619
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.